Reckitt Benckiser Group (OTCMKTS:RBGLY) Cut to “Equal Weight” at Morgan Stanley

Morgan Stanley downgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) from an overweight rating to an equal weight rating in a research note published on Monday, MarketBeat Ratings reports.

Several other research analysts have also weighed in on RBGLY. Barclays raised shares of Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Royal Bank Of Canada reissued an “outperform” rating on shares of Reckitt Benckiser Group in a research report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Reckitt Benckiser Group in a research report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

Reckitt Benckiser Group Trading Up 0.2%

Shares of RBGLY opened at $16.11 on Monday. Reckitt Benckiser Group has a 1 year low of $11.73 and a 1 year high of $16.30. The stock’s 50-day moving average price is $15.63 and its two-hundred day moving average price is $14.97. The company has a debt-to-equity ratio of 1.01, a quick ratio of 0.37 and a current ratio of 0.56.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.